| Name | Title | Contact Details |
|---|
ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney`s lead product candidate, REACT® (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT® has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting an immediate start to a global registrational program, which launched in the United States on schedule in January 2022. On January 18, 2022, ProKidney announced that it would become a publicly traded company via a business combination with Social Capital Suvretta Holdings Corp. III
CenterWatch is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
The Advisory Board is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Teva Neuroscience is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Kansas City, MO. To find more information about Teva Neuroscience, please visit www.tevaneuro.com
The Dolomite Centre / Syrris / Blacktrace is a Charlestown, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.